Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: REGN1033 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)

NCT01910220
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN1033 (SAR391786), placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Gainesville, Florida • Orlando, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2014 · Synced Nov 7, 2026, 3:13 PM EST
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

NCT06299098
View directory record Official record
Conditions
Obesity
Interventions
Trevogrumab-Part A, Trevogrumab-Part B and Part C, Garetosmab, Semaglutide, Matching Placebo-Part A, Matching Placebo-Trevogrumab, Matching Placebo-Garetosmab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,005 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
58
States / cities
Anniston, Alabama • Cullman, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Nov 7, 2026, 3:13 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects

NCT02741739
View directory record Official record
Conditions
Healthy
Interventions
REGN1033
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Nov 7, 2026, 3:13 PM EST
Completed Phase 2 Interventional

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

NCT01963598
View directory record Official record
Conditions
Sarcopenia
Interventions
REGN1033 (SAR391786), placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Anniston, Alabama • Phoenix, Arizona • El Cajon, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Nov 7, 2026, 3:13 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

NCT01507402
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN1033(SAR391786), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
Honolulu, Hawaii • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Nov 7, 2026, 3:13 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)

NCT01720576
View directory record Official record
Conditions
Healthy Volunteers
Interventions
REGN1033 (SAR391786), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Nov 7, 2026, 3:13 PM EST